Astal Laboratories board approved preferential allotment of 14.7 lakh equity shares at ₹40 each upon warrant conversion.
The company received ₹4.41 crore from 11 non-promoter investors for the conversion of warrants issued in November 2024.
Post-allotment, paid-up equity capital increased to ₹43.69 crore from ₹42.28 crore, comprising 43.86 lakh shares.